文献速递心脑血管急症

大梗死核心不受限尺寸卒中患者取栓治疗试验

Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size.
PubMed 文献 · N Engl J Med · 2024-01-01
一句话结论前循环近端闭塞伴大梗死(ASPECTS≤5)6.5小时内取栓加内科治疗较单纯内科治疗功能结局更好、死亡率更低,但症状性颅内出血发生率更高。

该试验将333例前循环近端血管闭塞且大梗死(ASPECTS≤5)患者按1:1随机分为取栓加内科治疗组(166例)和单纯内科治疗组(167例),9例因撤回同意或法律原因被排除分析。90天改良Rankin量表评分中位数取栓组为4、对照组为6(广义优势比1.63,95%CI 1.29-2.06,P<0.001)。90天全因死亡取栓组36.1%、对照组55.5%(校正相对危险度0.65,95%CI 0.50-0.84),症状性颅内出血分别为9.6%和5.7%(校正相对危险度1.73,95%CI 0.78-4.68)。试验因类似试验结果支持取栓而提前终止。

要点

  • 前循环近端闭塞伴大梗死(ASPECTS≤5)且发病6.5小时内患者,取栓加内科治疗较单纯内科治疗90天改良Rankin量表评分中位数更低(4 vs 6,广义优势比1.63,95%CI 1.29-2.06,P<0.001)。
  • 取栓组90天全因死亡率36.1%,对照组55.5%(校正相对危险度0.65,95%CI 0.50-0.84)。
  • 取栓组症状性颅内出血发生率9.6%,对照组5.7%(校正相对危险度1.73,95%CI 0.78至4.68)。
  • 取栓组发生11例操作相关并发症。
  • 约35%的患者接受了溶栓治疗。

适用人群与场景

  • 前循环近端脑血管闭塞且大梗死(磁共振成像或计算机断层扫描显示Alberta卒中项目早期CT评分≤5,分值范围0-10)的患者。
  • 症状发作后6.5小时内接受评估。

诊断标准与关键阈值

  • 大梗死定义为Alberta卒中项目早期CT评分≤5(分值范围0-10)。
  • 前循环近端脑血管闭塞。

处置流程与药物剂量

  • 取栓组:接受血管内取栓并接受内科治疗。
  • 对照组:仅接受内科治疗。

红旗征与不能漏的情况

  • 症状性颅内出血:取栓组9.6%,对照组5.7%(校正相对危险度1.73,95%CI 0.78至4.68)。

研究设计与关键结果

  • 研究类型:随机对照试验;共333例患者被分配至取栓组(166例)或对照组(167例),9例因撤回同意或法律原因被排除分析。
  • 试验因类似试验结果支持取栓而提前终止。
  • 约35%的患者接受了溶栓治疗。
  • 主要结局:90天改良Rankin量表评分中位数取栓组为4、对照组为6(广义优势比1.63,95%CI 1.29至2.06,P<0.001)。
  • 主要安全结局:90天全因死亡取栓组36.1%、对照组55.5%(校正相对危险度0.65,95%CI 0.50至0.84)。
  • 辅助安全结局:症状性颅内出血取栓组9.6%、对照组5.7%(校正相对危险度1.73,95%CI 0.78至4.68)。
  • 取栓组发生11例操作相关并发症。

证据类型、等级与局限

  • 证据类型:随机对照试验(LASTE,ClinicalTrials.gov注册号NCT03811769)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于急性卒中伴大梗死核心不受限尺寸的患者,取栓加内科治疗较单纯内科治疗功能结局更好、死亡率更低,但症状性颅内出血发生率更高。

指南或共识出处

  • 原文未引用指南或共识。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of thrombectomy in patients with acute stroke and a large infarct of unrestricted size has not been well studied.

METHODS: We assigned, in a 1:1 ratio, patients with proximal cerebral vessel occlusion in the anterior circulation and a large infarct (as defined by an Alberta Stroke Program Early Computed Tomographic Score of ≤5; values range from 0 to 10) detected on magnetic resonance imaging or computed tomography within 6.5 hours after symptom onset to undergo endovascular thrombectomy and receive medical care (thrombectomy group) or to receive medical care alone (control group). The primary outcome was the score on the modified Rankin scale at 90 days (scores range from 0 to 6, with higher scores indicating greater disability). The primary safety outcome was death from any cause at 90 days, and an ancillary safety outcome was symptomatic intracerebral hemorrhage.

RESULTS: A total of 333 patients were assigned to either the thrombectomy group (166 patients) or the control group (167 patients); 9 were excluded from the analysis because of consent withdrawal or legal reasons. The trial was stopped early because results of similar trials favored thrombectomy. Approximately 35% of the patients received thrombolysis therapy. The median modified Rankin scale score at 90 days was 4 in the thrombectomy group and 6 in the control group (generalized odds ratio, 1.63; 95% confidence interval [CI], 1.29 to 2.06; P<0.001). Death from any cause at 90 days occurred in 36.1% of the patients in the thrombectomy group and in 55.5% of those in the control group (adjusted relative risk, 0.65; 95% CI, 0.50 to 0.84), and the percentage of patients with symptomatic intracerebral hemorrhage was 9.6% and 5.7%, respectively (adjusted relative risk, 1.73; 95% CI, 0.78 to 4.68). Eleven procedure-related complications occurred in the thrombectomy group.

CONCLUSIONS: In patients with acute stroke and a large infarct of unrestricted size, thrombectomy plus medical care resulted in better functional outcomes and lower mortality than medical care alone but led to a higher incidence of symptomatic intracerebral hemorrhage. (Funded by Montpellier University Hospital; LASTE ClinicalTrials.gov number, NCT03811769.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Costalat V, Jovin TG, Albucher JF, et al. Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size. N Engl J Med. 2024. PMID: 38718358. doi:10.1056/NEJMoa2314063

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。